Dozens of Scientists Quit Texas Cancer Agency Review Panels, Claiming That Business Interests Trumped Merit

A publicly financed $3 billion effort to spur innovative cancer research, reduce cancer rates and speed up the commercialization of new treatments has floundered amid controversy after the mass resignation of nearly three dozen scientists, including two Nobel laureates, from review committees.
British Medical Journal